
Effects of buprenorphine on cocaine-base smoking in monkeys and self-administration of other reinforcing substances in rats and monkeys. Marilyn Carroll and Sylvie T. Lac. University of Minnesota, Minneapolis, Minnesota.


ISGIDAR Student Travel Award: A molecular analysis of fixed-ratio behavior maintained by alfentanil, cocaine and ketamine. Paul Skjoldager. University of Michigan, Ann Arbor, Michigan.

Invited Speaker: The role of the nucleus accumbens in the reinforcing action of drugs. George Koob. Scripps Clinic, LaJolla, California.


Choice between smoked and intravenous cocaine in humans. Richard Foltin and Marian Fischman. Johns Hopkins University, Baltimore, Maryland.
Minutes of last year's meeting were approved.

Treasurer David Downs reported that the balance of the ISGIDAR account prior to the 1990 meeting was $4,903.96. The proceeds from the Richmond meeting were $855.00, and the estimated expenses were $1,346.33, leaving a balance of approximately $4412.03. Two thousand dollars of this $4412.03 balance has been designated to support the travel of four ISGIDAR members to the CINP meeting. Note that these funds for travel to CINP were donated by pharmaceutical firms to support attendance at CINP.

President de Wit congratulated the 1990 winner of the Travel Award, Paul Skjoldager of the University of Michigan. She also expressed the organization's appreciation of the two invited speakers at the meeting, Mark Galizio and George Koob. Their presentations were interesting and informative and, as intended, broadened the scope of the ISGIDAR session. ISGIDAR members are again encouraged to submit names of potential invited speakers for next year's meeting, and as well names of candidates for the 1991 Travel Award.

It was announced that the following seven individuals had been accepted for membership in ISGIDAR, following a mail ballot vote: Rebecca Corwin, Ph.D., Department of Psychiatry, Cornell Medical Center; Bartley Hoebel, Ph.D., Department of Pharmacology, Princeton University; Mark S. Kleven, Ph.D., Department of Pharmacology, The University of Chicago; Michael A. Nader, Ph.D., Department of Psychiatry, The University of Chicago; Joy Schmitz, Ph.D., Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston; Peter Silverman, Ph.D., Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, and Rudy Vuchinich, Ph.D., Department of Psychology, Auburn University. Congratulations to all new members on their joining ISGIDAR.

The question of an increase in registration fees was raised. It was resolved that registration fees would be raised from $15 to $20.

Some members expressed a desire to have an organized lunch on the day of the ISGIDAR meeting. This will be arranged for the 1991 meeting.

Nancy Ator was thanked and recognized for her role in dealing with animal right's issues. She has carefully monitored developments in this area and has advised members on appropriate actions to support the use of animals in biomedical research.
The 1991 ISGIDAR meeting will be held on Sunday, June 16, at the Breakers Hotel in Palm Beach, Florida. As usual, ISGIDAR will be conducted as a satellite session of the Committee on Problems of Drug Dependence.

NEW INTERNATIONAL VICE-PRESIDENT

Dr. Tomoji Yanagita has stepped down as International Vice-President due to a large number of other commitments. President de Wit has appointed Dr. Koji Takada, also of the Central Institute for Experimental Animals, to fill out Dr. Yanagita's term of office. We are very grateful to Dr. Yanagita for his support and many years of service as the International Vice-President. The new International Vice-President, Dr. Takada, is an active member of ISGIDAR and was one of the first recipients of the ISGIDAR Travel Award.

MESSAGE FROM THE PRESIDENT

The 1990 ISGIDAR meeting in Richmond was a success, thanks to the efforts of CPDD, the local organizing committee in Richmond, Virginia and to all those who presented and participated. The science was of the highest quality, and the discussions were lively. A new, unscheduled addition to the agenda, very welcome after a sedentary day, was a jazzercise class under the expert direction of Suzette Evans. We hope this will become a regular feature of future ISGIDAR meetings.

ISGIDAR was invited by Tomoji Yanagita to present a symposium at the 17th Congress of the Collegium Internationale Neuropsychopharmacologicum (CINP), September 10-14, 1990 in Kyoto, Japan. Dr. Yanagita is serving as Secretariat of this CINP Congress. The suggested topic of the symposium was "Assessment of Reinforcing Properties of Drugs: A Determinant of Abuse Liability." The ISGIDAR symposium includes Nancy Ator as Chairperson with Tomoji Yanagita as Co-chairperson. The speakers selected are all ISGIDAR members engaged in research on drug reinforcement and who have been active contributors to ISGIDAR programs in recent years. An additional consideration was that the program encompass emerging issues in the vulnerability to drug abuse. The program to be presented is: Introduction to the Symposium—Laboratory Assessment of Drug Reinforcing Efficacy, N.A. Ator, The Johns Hopkins University; Enhancement of Reinforcing Efficacy by Development of Physical Dependence, K. Takada and T. Yanagita, Central Institute for Experimental Animals; Genetic Approaches to the Analysis of Addiction Processes, F.R. George, University of Maryland; Individual Differences in Drug Preferences in Humans, H. de Wit, University of Chicago; Behavioral and Pharmacological Strategies for Reducing Drug Abuse, M.E. Carroll, University of Minnesota. We believe that participation in international meetings such as this will relate to the broader, international community the validity and usefulness of studying drugs as reinforcers, research that has, until now, been conducted mostly (with some notable exceptions) within North America.

The CINP invitation required that ISGIDAR raise funds for travel and other expenses for our speakers. A number of pharmaceutical companies have very generously made donations to ISGIDAR to help defray the costs of the ISGIDAR symposium and this support will be acknowledged in the CINP Program. These companies are: Bristol-Myers Company, Wallingford, Connecticut; Duphar B.V. and Solvay-Mejl j Yakuhin, 1380 AA Weesp Holland; E.I. Du Pont de Nemours & Company, Wilmington, Delaware; Lilly Research Laboratories, Indianapolis, Indiana; Novo Nordisk A/S, CNS Division, Soeborg, Denmark;
A MESSAGE FROM NANCY ATOR, VICE-PRESIDENT (ANIMAL USE)

Status of U.S. Congressional Legislation and Animal Regulations pertaining to the Use of Animals in Research

Update on Animal Care Regulations: Part III of the revised USDA animal care regulations underwent complete revision in response to comments received during the public comment period ending in 1989. These regulations contain specific requirements for animal housing and care, including requirements related to the mandate of the Animal Welfare Act to promote the psychological well-being of captive primates and to provide exercise for dogs. A variety of factors were delaying republication of these regulations, and the Animal Legal Defense Fund reactivated a suit to force finalization of the new rules. USDA provided a schedule for republication of the rules to the federal court: final publication of the standards is to be completed by February 1991. A draft of these regulations covering only guinea pigs, rabbits, and hamsters was published as final in July 16, 1990. The portion of Part III dealing with dogs, cats, and nonhuman primates were published for public comment on August 15, 1990. The deadline for all comments in on or before October 1, 1990. The standards are in the Federal Register for that date, pp. 33447-33531. The head veterinarian at your institution may very well have a copy, and that may be the fastest way to review them if a library convenient to you does not receive the Fed Reg. Initial reaction is that this proposal is much improved over the original. The head of the White House Office of Science and Technology Policy, D. Allan Bromley, urged in the Spring that the rules be such that existing caging in research which would be usable for many more years, not become obsolete, that the rules be able to be justified scientifically, and that there be sufficient flexibility for investigators to exercise appropriate judgment about what is best for animals under their care. (Comments in "The Blue Sheet," 4/25/90).

Legislation: In June, the Animal Facilities Protection Act (HR 3270) was scheduled for hearing and markup by a subcommittee of the House Agriculture Committee. This is companion legislation to a similar Senate bill passed in November, 1989. On behalf of ISGIDAR I wrote to 14 of the subcommittee members to urge support for HR 3270 and to the 15th member, Rep. Charles Stenholm (D, TX), to thank him for introducing the legislation. The day of the ISGIDAR meeting, June 10, a large march was staged by those opposed to the use of animals in research to protest this same legislation. The subcommittee began acting preparatory to reporting the bill to the full Senate, but did not complete work at the time of the August recess. Some provisions of Senate bill S.891 which would prohibit the Food and Drug Administration from considering the results of the Draize test or LD50 tests unless the Secretary determined that no suitable alternatives were available were included in an amendment to the Farm Bill (s2830), but the Senate tabled the amendment and the provisions were not included in the Farm bill. Of the other pieces of legislation that were mentioned in the January 1990 newsletter, all had been referred to committee, but no actions had been taken on most of them by the time of the August recess. Hearings had been held on H.R. 3349 (Rep. H. Waxman, D-CA) Health Facilities Protection and Primate Center Rehabilitation Act; but the bill has not been reported to the House.

Please encourage your Congressional representative to become a member of the Animal Welfare Caucus if you have not already done so. The caucus was formed by Representative Vin Weber (R-MN) because he believes that the use of animals for legitimate purposes is being unfairly projected to the general public. I have written on behalf of ISGIDAR to representatives that were
being especially encouraged to join by the APA.

Support for Animal Researchers. ISGIDAR Past-President Marilyn Carroll was among the researchers using animals at the University of Minnesota whose home was targeted for picketing by PETA. Fortunately, the University responded promptly and positively to support these researchers. On behalf of ISGIDAR, I wrote letters of support for Marilyn and thanks to the University to members of the University administration. If any of you hear of similar campaigns directed against our colleagues, please let me know as soon as possible so that I can respond on behalf of ISGIDAR. (301-955-3135; FAX 301-955-0497).

INVITED SPEAKERS FOR THE 1991 MEETING

We are seeking suggestions for speakers to invite to the 1991 meeting. Invited speakers should be individuals who do not regularly attend the ISGIDAR meeting, and who are doing interesting research related to drugs as reinforcers. They will be paid a $100 honorarium. Members are urged to submit suggestions to Harriet de Wit.

1991 TRAVEL AWARD: STUDENT PAPER COMPETITION

ISGIDAR will again sponsor a Student Paper Competition Award for a new investigator to present a paper on drug self-administration research. Up to $500 in reasonable and documented travel costs will be paid to the winner to attend the meeting of the Committee on Problems of Drug Dependence, 1991 to present a paper at the ISGIDAR satellite session. Payment will be made upon submission of travel receipts to the ISGIDAR Treasurer. Those who did not receive the award, but who did receive good reviews will be encouraged to present their papers at the ISGIDAR meeting.

ELIGIBILITY: Applicants must be enrolled in a graduate program and be working toward a doctorate or have received their doctorate within the last five years (after June 1, 1988). Applicants who are not ISGIDAR members must be sponsored by an ISGIDAR member.

The research to be reported at ISGIDAR must not already be published.

MANUSCRIPT REQUIREMENTS: Papers should not be more than 10 pages excluding figures and references.

The length and scope of the paper should be consistent with a 20-25 minute slide presentation.

Please include paper title, name, address, phone number and author's signature on the cover page of the manuscript.

The signature and typed name of the author's sponsor should also appear on the cover page after a statement indicating that the applicant made a significant scientific contribution to the research.

Submit four copies, double-spaced.

REVIEW: Each manuscript will be independently reviewed by the ISGIDAR officers for originality, scientific contribution, sound methodology and clarity of the manuscript.

Blind review is possible upon request.
ISGIDAR BIBLIOGRAPHY

Listing of recent publications or manuscripts in press on the behavioral pharmacology of drugs of abuse by ISGIDAR members:

RA = published, reprints available
IP = in press
SU = submitted
NA = published, reprints not available

Dr. Marilyn E. Carroll
Department of Psychiatry
Box 392 UMHC
University of Minnesota
Minneapolis, MN 55455


Carroll, M.E. Phencyclidine self-administration is reduced by a nondrug alternative reinforcer: A behavioral economic analysis. 1990 (SU)
Carroll, M.E., and Lac, S.T. The effects of buprenorphine on I.V. cocaine self-administration in rats. 1990 (SU)

Dr. Harriet de Wit  
Department of Psychiatry  
The University of Chicago  
5841 S. Maryland  
Chicago, IL 60637


de Wit, H., Metz, J., and Cooper, M.D. Effects of ethanol, diazepam and amphetamine on regional cerebral metabolic rate: PET studies using FDG. *Neurobiological Approaches to Brain-Behavior interactions*, NIDA Research Monograph Series. (IP)

Dr. John R. Hughes  
Human Behavioral Pharmacology Laboratory  
Department of Psychiatry  
University of Vermont  
College of Medicine  
1 South Prospect Street  
Burlington, Vermont 05401


Kleven, M.S., Perry, B.D., Woolverton, W.L., and Seiden, L.S. Effects of repeated injections of cocaine on D1 and D2 dopamine receptors in rat brain. *Brain Research.* (SU)

Kleven, M.S., and Woolverton, W.L. Behavioral effects of continuous cocaine administration in rhesus monkeys. *Journal of Pharmacology and Experimental Therapeutics.* (SU)

Kleven, M.S., and Woolverton, W.L. The effects of bromocriptine and desipramine on behavior maintained by cocaine or food presentation in rhesus monkeys. *Psychopharmacology* 101: 208-213, 1990. (RA)

Kleven, M.S. and Woolverton, W.L. Effects of continuous infusion of the D1 antagonist SCH23390 on behavior maintained by cocaine or food presentation in rhesus monkeys. *Behavioral Pharmacology.* (IP)

Nader, M.A., and Woolverton, W.L. Effects of increasing the magnitude of an alternative reinforcer on drug choice in a discrete-trials choice procedure. *Journal of Pharmacology and Experimental Therapeutics.* (SU)


Williams, J.E.G. and Woolverton, W.L. The D2 agonist quinpirole potentiates the discriminative stimulus effects of the D1 agonists SKF 38393. *Pharmacology Biochemistry and Behavior* (IP)

Woolverton, W.L. Cocaine self-administration: Pharmacology and behavior. *NIDA Research Monograph Series.* (IP)

ISGIDAR BIBLIOGRAPHY FORM

(RA) Published, reprints available
(IP) In Press, reprints will be mailed after publication
(NA) Reprints unavailable
(SU) Submitted

In submitting your entries, use any useful format. Mail this form to:

Dr. Richard A. Meisch
Dept. of Psychiatry
UTHSC-H
1300 Moursund
Houston, TX 77030-3406

Note: If the response cost is less to just mail a copy of the preprint or reprint, please feel free to do so with ISGIDAR written on the envelope or the paper itself.

Address for reprints:

__________________________________________________________________________

__________________________________________________________________________

__________________________________________________________________________

__________________________________________________________________________

__________________________________________________________________________

Citations (in alphabetical order)